Oncology Central

Management of leptomeningeal metastasis in patients with lung cancer

0

Leptomeningeal metastasis (LM) is a rare complication of lung cancer. It occurs in approximately 1–6% of patients with lung cancer and it is most commonly associated with adenocarcinoma (50–56%), followed by squamous cell carcinoma (26–36%) and small cell carcinoma (13–14%) [1]. Lung cancer patients harboring activating mutations in EGFR are associated with prolonged disease control and survival when tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib are used.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.